Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary objective:

• To determine if irbesartan 300mg is better than 150mg in protecting the kidneys in hypertensive patients with diabetes and microalbuminuria.

Secondary objectives:

• To determine how well irbesartan 300mg is tolerated versus 150mg

• To determine the percentage of patients reaching the blood pressure target of 130/80 mmHg

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Collaborator: Bristol-Myers Squibb
• Treatments: Irbesartan

Criteria

Inclusion Criteria:

• Hypertensive patients, treated or untreated, with type 2 diabetes and urinary albumin excretion rate 20-200ug/min.

• Blood pressure of < 180/110mmHg at baseline

• Normal serum creatinine

Exclusion Criteria:

• Type 1 diabetes

• Use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers in the 5 weeks before recruitment

• Pregnant or lactating women

• Severe hypertension

• Overt nephropathy

• Allergy to study drug

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.